[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354035-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354035-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-radio-genomics-biomarker-for-precision-epidermal-growth-factor-receptor-mutation-targeting-therapy-in-non-small-cell-lung-cancer","A radio-genomics biomarker for precision epidermal growth factor receptor mutation targeting therapy in non-small cell lung cancer","","Developing reliable first-line selection for EGFR-targeted therapy in non-small cell lung cancer requires distinguishing “exclusive” EGFR mutation without co-occurring actionable alterations, since co-mutations can weaken EGFR-TKI response. A CT-based radiomics signature, EGFR-RPV, was trained in a multi-centre cohort (n=304) and validated in an independent testing set (n=51), using paired imaging and genomics, plus transcriptomics enrichment. EGFR-RPV predicted exclusive EGFR mutation with accuracies of 0.77 and 0.71 and stratified prognosis, supporting a non-invasive biomarker for clinical decision-making.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-radio-genomics-biomarker-for-precision-epidermal-growth-factor-receptor-mutation-targeting-therapy-in-non-small-cell-lung-cancer/354035/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-radio-genomics-biomarker-for-precision-epidermal-growth-factor-receptor-mutation-targeting-therapy-in-non-small-cell-lung-cancer/354035.png","ImageObject",300,407,{"name":42,"@type":43},"Taylor Morgan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is identifying exclusive EGFR mutation important for first-line EGFR-TKI therapy?","Question",{"text":63,"@type":64},"Co-mutations involving EGFR and other targetable genes can reduce treatment response. Exclusive EGFR mutation, defined by the absence of other actionable alterations, represents a more favourable clinical scenario for first-line EGFR-TKI use.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the EGFR-RPV radiomics signature developed and validated?",{"text":68,"@type":64},"EGFR-RPV was developed using CT-based radiomics in a multi-centre cohort with paired imaging and genomics data (n=304), then validated in an independent testing set (n=51), supported by transcriptomics enrichment analysis.",{"name":70,"@type":61,"acceptedAnswer":71},"What performance and clinical associations did EGFR-RPV show?",{"text":72,"@type":64},"EGFR-RPV predicted exclusive EGFR mutation with accuracies of 0.77 (95% CI 0.66–0.88) and 0.71 (95% CI 0.54–0.89) in internal and external testing, respectively, and it stratified patient prognosis using a hazard ratio of 2.15 (95% CI 1.50–3.08).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354035,1790551953,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nA radio-genomics biomarker for precision epidermal growth factor receptor mutation targeting therapy in non-small cell lung cancer  \nMitchell Chen1,2,5􀀍, Susan J. Copley2, Kristofer Linton-Reid1, Patrizia Viola3, Yidong Han2, Alessio Cortellini1,4, Haonan Lu1, Aleksander Mani2, Marize Bahket2, David J. Pinato1, Danielle Power2, Andrea G. Rockall1,2 & Eric O. Aboagye1  \nNewer-generation tyrosine kinase inhibitors (TKIs) have shown increasing efficacy in cancers driven by specific mutations, with epidermal growth factor receptor (EGFR) alterations remaining the most common actionable targets in non-small cell lung cancer (NSCLC). Treatment decisions are currently guided by tissue sampling and genetic testing, which are limited by procedural risks, patient tolerance, tumour heterogeneity and mutation evolution. Because co-mutations involving EGFR and other targetable genes can diminish treatment response, identifying exclusive EGFR mutation, defined by the absence of other actionable alterations, represents a clinically favourable scenario for first-line EGFR-TKI therapy. We developed a CT-based radiomics signature, EGFR-RPV, to predict exclusive EGFR mutational status using NSCLC patients (n = 304) from a multi-centre cohort with paired imaging and genomics data, and validated performance in an independent testing set (n = 51), alongside transcriptomics enrichment analysis. EGFR-RPV predicted exclusive EGFR mutation with accuracies of 0.77 (95% CI 0.66–0.88) and 0.71 (95% CI 0.54–0.89) in internal and external testing, respectively, and stratified patient prognosis (hazard ratio 2.15, 95% CI 1.50–3.08) . FAM190A and CBMO1 were enriched in exclusive EGFR-positive cases, consistent with their roles in cell division regulation and vitamin A biosynthesis, respectively. EGFR-RPV thus offers a non-invasive approach to identify exclusive EGFR mutations, with a potential role in guiding first-line EGFR-TKI use.  \nKeywords Non-small cell lung cancer, Imaging biomarker, Radiogenomics, EGFR mutation, Tyrosine kinase inhibitor  \nLung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 80–85% of its cases1. Over 70% of NSCLC cases are diagnosed at advanced stages, carrying poor prognoses2. Tyrosine kinase inhibitors (TKI) have excellent response profile in cancers exhibiting certain oncogenic driver mutations, with those relating to epidermal growth factor receptor (EGFR) being the most common targets in NSCLC3. Newer generation EGFR-TKIs, such as osimertinib, are more effective against advanced and metastatic NSCLC, with prolonged patient survival, improved quality of life and fewer adverse events compared to chemotherapy4, and are now the first line therapy for cancers harbouring suitable mutations5. In precision EGFR-TKI clinical pathways, it is crucial to ensure timely commencement of therapies to maximise patient benefit, avoid unnecessary treatment-related adverse events6, and select the best first-line treatment. For example, in the case of immune checkpoint inhibitor (ICI), increased pneumotoxicity has been observed in patients with EGFR mutation7. Treatment decision is currently guided by tissue sampling followed  \n1Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK. 2Imperial College Healthcare NHS Trust, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK. 3NorthWest London Pathology, Charing Cross Hospital, London W6 8RF, UK. 4Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Rome 00128, Italy. 5Imperial Centre for Translational and Experimental Medicine (ICTEM), Hammersmith Campus Du Cane Road, London, UK. 􀀍 email: [mitchell.chen@imperial.ac.uk](mitchell.chen@imperial.ac.uk)  \n[www. nature.com/scientificreports/](www. n","cbCaifa6jrHyr3FQ","https://ap.wps.com/l/cbCaifa6jrHyr3FQ","pdf",3050895,14,"English","# Background\n## Limitations of tissue and liquid biopsy\n## Need for non-invasive biomarkers\n# Method\n## CT-based radiomics signature EGFR-RPV\n## Cohort design and validation\n## Transcriptomics enrichment analysis\n# Results\n## Predictive performance for exclusive EGFR mutation\n## Prognostic stratification and biological signals","[{\"question\":\"Why is identifying exclusive EGFR mutation important for first-line EGFR-TKI therapy?\",\"answer\":\"Co-mutations involving EGFR and other targetable genes can reduce treatment response. Exclusive EGFR mutation, defined by the absence of other actionable alterations, represents a more favourable clinical scenario for first-line EGFR-TKI use.\"},{\"question\":\"How was the EGFR-RPV radiomics signature developed and validated?\",\"answer\":\"EGFR-RPV was developed using CT-based radiomics in a multi-centre cohort with paired imaging and genomics data (n=304), then validated in an independent testing set (n=51), supported by transcriptomics enrichment analysis.\"},{\"question\":\"What performance and clinical associations did EGFR-RPV show?\",\"answer\":\"EGFR-RPV predicted exclusive EGFR mutation with accuracies of 0.77 (95% CI 0.66–0.88) and 0.71 (95% CI 0.54–0.89) in internal and external testing, respectively, and it stratified patient prognosis using a hazard ratio of 2.15 (95% CI 1.50–3.08).\"}]","A radio-genomics biomarker for precision epidermal growth factor receptor mutation targeting therapy in non-small cell lung cancer | PDF",1790108542,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78b1a46201d4fd897f4747a03ad09683.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b0013903ab04a108b98204f1e103fa7.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d34e3bf91e4d162a8ce4428c6f29cad.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd894db5858eaffbf1b525d03bd24917.webp",980,1287]